Ebola virus convalescent blood products

Where we are now and where we may need to go

Thierry Burnouf, Jerard Seghatchian

研究成果: 雜誌貢獻回顧型文獻

16 引文 (Scopus)

摘要

The world is regularly exposed to emerging infections with the potential to burst into a pandemic. One possible way to treat patients, when no other treatment is yet developed, is passive immunization performed by transfusing blood, plasma or plasma immunoglobulin fractions obtained from convalescent donors who have recovered from the disease and have developed protective antibodies. The most recent on-going epidemic is caused by the Ebola virus, a filovirus responsible for Ebola virus disease, a severe, often lethal, hemorrhagic fever. Recently, the use of convalescent blood products was proposed by the WHO as one early option for treating patients with Ebola virus disease. This publication provides an overview of the various convalescent blood products and technological options that could theoretically be considered when there is a need to rely on this therapeutic approach. In countries without access to advanced blood-processing technologies, the choice may initially be restricted to convalescent whole blood or plasma. In technologically advanced countries, additional options for convalescent blood products are available, including virally inactivated plasma and fractionated immunoglobulins. The preparation of minipool immunoglobulins is also a realistic option to consider.
原文英語
頁(從 - 到)120-125
頁數6
期刊Transfusion and Apheresis Science
51
發行號2
DOIs
出版狀態已發佈 - 2014

指紋

Ebolavirus
Ebola Hemorrhagic Fever
Immunoglobulins
Passive Immunization
Pandemics
Fever
Tissue Donors
Technology
Antibodies
Therapeutics
Infection

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

引用此文

Ebola virus convalescent blood products : Where we are now and where we may need to go. / Burnouf, Thierry; Seghatchian, Jerard.

於: Transfusion and Apheresis Science, 卷 51, 編號 2, 2014, p. 120-125.

研究成果: 雜誌貢獻回顧型文獻

@article{aef38c78f58e4a719407918b31d10f19,
title = "Ebola virus convalescent blood products: Where we are now and where we may need to go",
abstract = "The world is regularly exposed to emerging infections with the potential to burst into a pandemic. One possible way to treat patients, when no other treatment is yet developed, is passive immunization performed by transfusing blood, plasma or plasma immunoglobulin fractions obtained from convalescent donors who have recovered from the disease and have developed protective antibodies. The most recent on-going epidemic is caused by the Ebola virus, a filovirus responsible for Ebola virus disease, a severe, often lethal, hemorrhagic fever. Recently, the use of convalescent blood products was proposed by the WHO as one early option for treating patients with Ebola virus disease. This publication provides an overview of the various convalescent blood products and technological options that could theoretically be considered when there is a need to rely on this therapeutic approach. In countries without access to advanced blood-processing technologies, the choice may initially be restricted to convalescent whole blood or plasma. In technologically advanced countries, additional options for convalescent blood products are available, including virally inactivated plasma and fractionated immunoglobulins. The preparation of minipool immunoglobulins is also a realistic option to consider.",
keywords = "Blood, Convalescent plasma, Ebola, Emerging pathogens, Immunoglobulins, Mini-pool, Plasma, Transfusion, Viral inactivation, Virus",
author = "Thierry Burnouf and Jerard Seghatchian",
year = "2014",
doi = "10.1016/j.transci.2014.10.003",
language = "English",
volume = "51",
pages = "120--125",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Ebola virus convalescent blood products

T2 - Where we are now and where we may need to go

AU - Burnouf, Thierry

AU - Seghatchian, Jerard

PY - 2014

Y1 - 2014

N2 - The world is regularly exposed to emerging infections with the potential to burst into a pandemic. One possible way to treat patients, when no other treatment is yet developed, is passive immunization performed by transfusing blood, plasma or plasma immunoglobulin fractions obtained from convalescent donors who have recovered from the disease and have developed protective antibodies. The most recent on-going epidemic is caused by the Ebola virus, a filovirus responsible for Ebola virus disease, a severe, often lethal, hemorrhagic fever. Recently, the use of convalescent blood products was proposed by the WHO as one early option for treating patients with Ebola virus disease. This publication provides an overview of the various convalescent blood products and technological options that could theoretically be considered when there is a need to rely on this therapeutic approach. In countries without access to advanced blood-processing technologies, the choice may initially be restricted to convalescent whole blood or plasma. In technologically advanced countries, additional options for convalescent blood products are available, including virally inactivated plasma and fractionated immunoglobulins. The preparation of minipool immunoglobulins is also a realistic option to consider.

AB - The world is regularly exposed to emerging infections with the potential to burst into a pandemic. One possible way to treat patients, when no other treatment is yet developed, is passive immunization performed by transfusing blood, plasma or plasma immunoglobulin fractions obtained from convalescent donors who have recovered from the disease and have developed protective antibodies. The most recent on-going epidemic is caused by the Ebola virus, a filovirus responsible for Ebola virus disease, a severe, often lethal, hemorrhagic fever. Recently, the use of convalescent blood products was proposed by the WHO as one early option for treating patients with Ebola virus disease. This publication provides an overview of the various convalescent blood products and technological options that could theoretically be considered when there is a need to rely on this therapeutic approach. In countries without access to advanced blood-processing technologies, the choice may initially be restricted to convalescent whole blood or plasma. In technologically advanced countries, additional options for convalescent blood products are available, including virally inactivated plasma and fractionated immunoglobulins. The preparation of minipool immunoglobulins is also a realistic option to consider.

KW - Blood

KW - Convalescent plasma

KW - Ebola

KW - Emerging pathogens

KW - Immunoglobulins

KW - Mini-pool

KW - Plasma

KW - Transfusion

KW - Viral inactivation

KW - Virus

UR - http://www.scopus.com/inward/record.url?scp=84922620862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922620862&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2014.10.003

DO - 10.1016/j.transci.2014.10.003

M3 - Review article

VL - 51

SP - 120

EP - 125

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 2

ER -